Lupus Nephritis Dug Pipeline Landscape Report : Therapeutic Assessment by 2024 by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) had its price target lowered by analysts at HC Wainwright from $7.00 to $6.00. They now have a "neutral" rating on the stock.
institutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% drop [Yahoo! Finance]
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) had its price target lowered by analysts at Wells Fargo & Company from $44.00 to $24.00. They now have an "overweight" rating on the stock.
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024 [Yahoo! Finance]